Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CDKI-73 |
Synonyms | |
Therapy Description |
CDKI-73 is a kinase inhibitor that blocks CDK9, CDK1, and CDK2 activity, which may lead to apoptotic activity and inhibition of cell proliferation and tumor growth (PMID: 30194564, PMID: 24495868, PMID: 32368391). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CDKI-73 | CDK1 Inhibitor 13 CDK2 Inhibitor 31 CDK9 Inhibitor 21 | CDKI-73 is a kinase inhibitor that blocks CDK9, CDK1, and CDK2 activity, which may lead to apoptotic activity and inhibition of cell proliferation and tumor growth (PMID: 30194564, PMID: 24495868, PMID: 32368391). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A fusion | acute myeloid leukemia | sensitive | CDKI-73 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CDKI-73 treatment inhibited Cdk9 kinase activity and viability, and induced apoptosis in acute myeloid leukemia cell lines harboring KMT2A fusions in culture, and inhibited tumor growth and induced regression in a cell line xenograft model (PMID: 30194564). | 30194564 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|